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aBstraCt
In the healthy organism, there is a constant balance between the formation and neutralization of free radicals. 
Oxidative stress is a result of free radicals’ production and naturalization imbalance, in favor of the free radicals’ 
high concentration. Literature suggests the existence of the relationship between decreased intraocular antioxidant 
capacity and ocular diseases. Retina and the photoreceptors in particularl, are susceptible to oxygen deficiency due 
to their great oxygen consumption. The aim of this review was to describe the relationship between oxidative stress 
and the most common vitreoretinal disorders. The authors focused on four ocular diseases such as vitreous degenera-
tion, rhegmatogenous retinal detachment, age-related macular degeneration and diabetic retinopathy. It was widely 
proven that high oxidative stress damages retina by the acceleration of photoreceptors and ganglion cells apoptosis. 
Available data suggesting that substances scavenging oxidative stress may be effective in slowing down the progression 
of these degenerative ocular diseases. However, the effects of antioxidants treatment are ambiguous, successful results 
of experimental studies lead straight to clinical use in human in the future. 
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introduCtion
Oxygen is the essential vital chemical element. 
It can be either consumed by the cells remaining in 
its molecular form or be transformed into insoluble 
reactive oxygen species (ROS). Reactive oxygen de-
rivatives such as superoxide aions (O2–), hydrogen 
peroxide (H2O2), hydroxyl radical (OH–), peroxyl 
radical and singlet oxygen are the most common rad-
icals in the organisms [1]. Free radicals are the mol-
ecules containing unpaired electrons making them 
capable of independent existence. The unpaired elec-
tron makes the molecules highly reactive. They can 
either donate an electron or extract an electron from 
other molecules, behaving as a reductant or oxidant. 
Vivid reactivity of radicals is the cause of their short 
half-life (10-4 seconds or less) in any biological en-
vironment [2]. In the healthy organism, there is 
a constant balance between the formation and neu-
tralization of free radicals. Free radicals’ formation 
is a natural consequence of cellular functioning, but 
one has to remember that exogenous factors can 
trigger radicals’ overproduction. Any substance or 
molecule with the capacity of delaying or inhibiting 
oxidation of other substance is generally defined as 
an antioxidant. There are different types of antioxi-
dants, they can be both exogenous and endogenous, 
but they are all responsible for the prevention of 
radicals’ induced cell damage and death. All antioxi-
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dants can by divided into three main groups — anti-
oxidant enzymes, chain-breaking antioxidants and 
metal bonding proteins [2]. 
Oxidative stress is a result of free radicals’ pro-
duction and naturalization imbalance, in favor of 
the free radicals’ high concentration. The imbalance 
can be either due to overproduction of endogenous 
ROS by mitochondrial respiration or decreased 
antioxidant capacity [3]. ROS damage range of 
molecular elements including proteins, lipids and 
nucleic acids (DNA and/or RNA). These cellular 
structures destruction contributes to cell aging, ac-
celeration of genetically programmed cell death or 
apoptosis [1]. There are suggestions in the literature 
concerning the relationship between decreased in-
traocular antioxidant capacity and the ocular dis-
eases. Several age-related ocular diseases have been 
described as associated with oxidative stress, such 
as Fuch’s dystrophy, nuclear cataract, age-related 
macular degeneration (AMD), diabetic retinopathy 
(DR) [4].
The aim of this review was to describe the rela-
tionship between oxidative stress and vitreoretinal 
disorders. 
Vitreous degeneration 
Vitreous body is the biggest structural compo-
nent of the eye, being roughly 80% of the total 
globe size. Vitreous cavity is the space between 
the posterior lens surface and the inner limiting 
membrane (ILM) of the retina.  Vitreous has ap-
proximately 4ml of volume and it is built of wa-
ter (99%), collagen fibres, non-collagen proteins, 
glucosaminoglycans (e.g. hyaluronic acid) [5]. It is 
relatively acellular with only one layer of mononu-
clear phagocytes and hyalocytes in the posterior part 
of its cortex [6]. Due to its clarity vitreous enables 
the photons  to freely penetrate to posterior eye ele-
ments, such as retina. It also takes part in maintain-
ing intraocular pressure and intraocular oxygen ten-
sion. As vitreous body is an avascular structure it has 
no capacity of regeneration once it is damaged [7].
Vitreous degeneration is a physiological age-re-
lated process resulting from gel liquefaction and 
concurrent dehiscence of vitreoretinal adhesion [8]. 
As the gel liquefies the adhesion of vitreal body 
to retina weakens. In consequence vitreal cortex 
separates totally form the ILM of the retina, which 
literature refers as posterior vitreous detachment 
(PVD). Although it is said that vitreous degen-
eration is a physiological phenomemnon, there are 
factors which can facilitate the process. Increased 
oxidative stress biomarkers and increased activity 
of proteolytic enzymes are said to be positively cor-
related with the vitreous degeneration [9]. A high 
concentration of ROS induced by light was pre-
sented as the liquefication factor to be age-related by 
Uneo and collegues [10]. It was also proven that free 
radicals, such as  hydroxyl radical (OH–) and super-
oxide anion (02–), generated by visible light irradia-
tion, contribute to vitreous liquefaction [11].  Berra 
and associates found that the antioxidative potential 
of human vitreous decrease with age which contrib-
ute to subsequent oxidative-stress-induced retinal 
pathologies [12]. 
retinal detaChMent
Rhegmatogenous retinal detachment (RRD) 
is one of the ophthalmological emergencies. The 
epidemiology of RRD varies. Different studies show 
there is 1 person per 10.000 yearly [13] while others 
estimate the incidence of approximately 6–18 cases 
for every 100.000 people a year [14]. Following 
the definition retinal detachment occurs when the 
neurosensory retina (NSR) separates from the reti-
nal pigment epithelium (RPE). There are four types 
of retinal detachment distinguished on the basis of 
the underlying cause. The majority of RRD cases 
derives from the retinal break which becomes an 
entrance to subretinal space. Leakage of the vitre-
ous cavity fluid leads to separation of the NSR [15]. 
Detached sensory retina is deprived of oxygen and 
nutrients, thus leading to stress conations and ROS 
overproduction in photoreceptors [16]. Both pho-
toreceptors and RPE are very susceptible to ROS 
formation due to their high proportion of fatty 
acids, high oxygen consumption and permanent 
exposure to sunlight. 
Study shows that biological antioxidative poten-
tial (BAP) was significantly deceased in the vitre-
ous fluid of patients with RRD. Oxidative stress 
was elevated as the result of retinal cells damage. 
What is more, authors imply that the level of BAP 
seems to be correlated only with the extent of reti-
nal detachment, with no proved correlation with 
duration, presence of proliferative vitreoretinopa-
thy (PVD), vitreous hemorrhage (HV), macular 
status or patients’ age [17]. Photoreceptors are very 
susceptible to oxygen deficiency due to their great 
oxygen consumption. They have a large number 
of mitochondria to fulfil their metabolic demand. 
A detachment of neurosensory retina form under-
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lying retinal segments leads to hypoxic stress and 
other nutrients deprivation. The exact mechanism 
of cell death is not yet clearly known. It was found 
that oxidative stress causes mitochondrial and ex-
tra-mitochondrial aerobic ATP synthesis leading to 
ROS overproduction. Elevated ROS concentration, 
however, is proven to accelerate cell apoptosis. The 
experimental study questioned whether decrease 
of oxidative stress would have an effect on mito-
chondrial dynamics in photoreceptors after retinal 
detachment. The outcomes showed inhibition of 
essential mitochondrial fission mediator and de-
creased photoreceptor death [18]. A different study, 
conducted on the experimental retinal detachment, 
proved successfull photoreceptors protection by 
antioxidative substances as edaravone or taurourso-
deoxycholic acid [19]. Another antioxidant factor 
— N-acetylocysteine (NAC) was specifically exam-
ined for its possible use in preventing retinal detach-
ment, secondary do PVR. N-acetylcysteine, a ROS 
scavenger, was introduced subretinally at the time of 
RD induction. The experiment was conducted on 
rabbit eyes and cell models. The outcome showed 
that N-acetylcysteine (NAC) effectively decreased 
the accumulation of ROS. Although NAC therapy 
prevented rabbits from retinal detachment itself, 
the majority of the animals treated still developed 
PVR membranes. This study makes one consider 
the future therapeutic use and clinical application of 
N-acetylocysteine in prevention of RD [20]. 
age-related MaCular degeneration
Age-related macular degeneration (AMD) is 
listed as one of the XXI-century diseases [21]. It 
is macular pathology of the elderly. Its incidence 
increases with age however it usually does not af-
fect people before 50 years of age. The course of the 
disease may have different rates of development. 
Any type causes irreversible visual impairment, 
gradually leading to blindness if left untreated. Re-
searchers estimate that the number of individuals 
with AMD to be 196 million in 2020 with the 
tendency to increase to 288 million in 2040 [22]. 
AMD is generally characterized as drusen, patholo-
gies of pigment epithelium (RPE) or pathological 
vessels formation in the central retina. Literature 
classifies AMD into two types — “dry” and “wet”. 
The first type called ‘dry-type AMD’ is the great 
majority of cases, being approximately 90% of the 
population suffering from AMD. It is described as 
the formation of drusen — deposits of metabo-
lism products localized between RPE and Bruch’s 
membrane. RPE is very susceptible to ROS influ-
ence mostly due to its high oxygen consumption 
and exposure to light. As the AMD progresses, the 
degeneration of RPE spreads through resulting in 
“geographical atrophy” (GA), well visible in fundus 
examination. Approximately 10–15% of patients 
suffer from “wet-type AMD”. Vision impairment 
in this AMD type is greater and the course of the 
disease is more rapid in comparison to dry-type. 
Clinically it is characterized as the choroidal neo-
vascularization (CNV) or pigment epithelium de-
tachment (PED). Newly formed sub-RPE vessels 
are very weak which leads to vascular leakages or 
hemorrhage causing further retina destruction and 
vision loss [23]. The only advantage of the rapidly 
progressing wet-type AMD over the dry-type AMD 
is the treatment method. Currently, there is no tar-
geted treatment for early-stage drusen formation 
nor advanced geographic atrophy in dry AMD. On 
the contrary, patients suffering from wet AMD can 
be successfully treated with intraocular anti-VEGF 
injections (anti-vascular endothelial growth factor). 
It has been widely proven that antioxidant activ-
ity decreases with age. Moreover, the level of ROS 
increases, and thus the total antioxidant capacity of 
any tissue [24]. Age-related macular degeneration is 
still being tested for genetical inheritance. Studies 
had shown individuals with the complement factor 
H (CFH) polymorphism of Y402H are at greater 
risk of suffering from AMD. This type of poly-
morphism reduces the CHF’s ability to neutralize 
the effect of oxidized photoreceptor phospholipids, 
which later triggers RPE cells’ apoptosis [25]. Reti-
nal pigment epithelium damage is observed even in 
the early stages of AMD, however, the correlation 
between the damage extent with the OS and dis-
ease progression has not been found [26]. Retinal 
pigment epithelium cells are known to have high 
metabolic activity. The two-compound pigment of 
macula (zeaxantin and lutein) is the barrier, which 
protects the cells form oxidative stress [27]. The cells 
themselves have their own antioxidant system. The 
NRF-2/ARE (nuclear factor-erythroid 2-related fac-
tor-2/antioxidant response element) complex plays 
great role in the oxidative stress regulation [28]. In 
the oxidative stress environment, the NRF-2 has 
released the complex and is tan moved from cyto-
stol to  cell nucleus allowing antioxidant system to 
be activated [29]. The experimental study on mice 
models, proved that the loos of NRF-2 gene caused 
more intensive oxidative stress and what is more the 
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RPE became more susceptible to oxidative damage 
[30]. On the contrary to inheritance, AMD RPE 
damage can be also caused by environmental fac-
tors. These modifiable external factors; they are ciga-
rettes smoking or high fat consumption. The exact 
correlation between cigarette smoking and AMD 
progression is not yet clearly known. However, data 
shows substances from cigarette smoke diminish 
tissues from ascorbic acid and protein sulphyrdyl 
groups, leading to DNA, lipids and proteins oxida-
tion and damage. 
The molecular changes, like these caused by ciga-
rette smoke, have been described in AMD. This fact 
could lead to assumption that oxidative damage is 
one of the factors in the mechanism of AMD disease 
development or progression. The same observations 
had been made in the multiple studies concluding 
that smoking is the strongest environmental risk 
factor for AMD [31].
diaBetiC retinopathy
Diabetes is a major cause of secondary blindness 
in developed countries in people of working age. 
It is a civilization disease and a great epidemiologi-
cal problem. It is estimated that over 420 million 
people with diabetes currently live in the world. 
World Health Organisation predicts that diabetes 
will become the seventh death cause by 2030 [32]. 
The vast majority of diabetics, reaching even 90%, 
are people with type 2 diabetes. It is now believed 
that in the next 15–20 years the number of diabetics 
in Poland will double. All patients with diagnosed 
diabetes and those with pre-diabetes are at risk of 
complications. The most important concern blood 
vessels (angiopathies) in the kidneys, brain, heart 
and eyes. Diabetic retinopathy is a complication as-
sociated with retinal vascular remodelling resulting 
from chronic hyperglycemia. Unfavorably for the 
patients, complications occur regardless of the type 
of diabetes. On the other hand, numerous studies 
had confirmed that the duration of the underlying 
disease has the greatest impact on the development 
of retinopathy. Treatment of complications is often 
difficult, sometimes unsatisfactory for the patient 
and an ophthalmologist. good glycemic control is 
still the most important Among all the methods of 
treating diabetes and its complication.
Glucose is known to be the main source of ener-
gy in organisms. Its metabolism in the cells involves 
redox reactions to produce energy by transport, 
storage or extraction of electrons. [33]. In the con-
ditions of normal glycemic level, glucose undergoes 
the glycolysis pathway to produce ATP in the Kreb’s 
cycle in the mitochondria, where electrons are be-
ing stored in form reduced form of Nicotinamide 
adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2 [34]. ROS production takes 
place in mitochondria by two processes, one is the 
mitochondrial oxidative phosphorylation and the 
second NADH oxidase system (Nox). It had been 
described that over 95% of oxygen transformations 
take place in the mitochondria. Approximately 
1–5% of these reactions result in ROS production. 
In the environment of hyperglycemia, increased 
level of ROS stabilizes hypoxia-inducible factor 1a 
(HIF-1a) leading to upregulation of angiogenic 
genes e.g. VEGF [35]. Data form the experiment 
had shown an increased level of VEGF in vitreous 
body of patients with proliferative diabetic retinopa-
thy. Eye fundus examination revealed pathological 
neovascularization in retina, secondary to VEGF 
increased concentration [36]. 
Another study described the evidence for the 
correlation between oxidative stress and the sever-
ity of diabetic retinopathy. Retinal vessels’ damage 
is caused by four major metabolic mechanisms- 
increases polyol pathway flux, activation of the 
protein kinase C (PKC) pathway, increased intra-
cellular formation of advanced glycation end-pro-
teins (AGEs) and expression of their receptors, 
and hexosamine activation pathway. All of these 
mechanisms have been positively correlated with 
increased oxidative stress and ROD overproduction 
[37]. On the other hand, obesity and dyslipidemia 
are different external factors leading to ROS over-
production, by fatty acids oxidation with NADPH 
oxidase. Experimental data showed that degenera-
tion of retinal vessels could be reduced by antioxi-
dant agents by activation of caspase-3 and nuclear 
factor-kB (NF-kB), which lead to the assumption 
that oxidative stress is one of the factors causing 
capillary apoptosis [38]. 
Longtime clinical observations suggest that de-
creasing oxidative stress may become part of DR 
treatment, as they delay or inhibit pathological met-
abolic pathways producing ROS [39].
ConClusions
It is proven that high oxidative stress damages 
retina, by the acceleration of photoreceptors and 
ganglion cells apoptosis. The denegation of retina, 
irrespective of the type, especially in macular dis-
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eases, causes vision impaired. In great majority 
of retinal diseases improvement prognosis is very 
poor. Oxidative stress agents, their influence on 
particular tissues, the oxidant-antioxidant balance 
is being still explored. Treatment is being aimed 
to cure the disease in its asymptomatic stage, to 
prevent vision impairment. Available data suggest 
that substances scavenging oxidative stress may be 
effective slowing down the progression of these 
degenerative ocular diseases. Therefore, inhibition 
of the metabolic pathways, producing a high con-
centration of ROS, may become protective for reti-
nal cells. Currently, there are only cell or animal 
models studies proving beneficial use of antioxi-
dants in the prevention of retinal damage. Devel-
opment of the treatment for retinal degeneration 
still faces great challenges and further investigation 
is needed. However, predicted effects of antioxi-
dant treatment are ambiguous, successful results 
of experimental studies lead straight to clinical use 
in human in the future. 
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